sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses New Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed a Form 8.3 disclosing its interest in Avadel Pharmaceuticals plc. As of February 2, 2026, Vanguard holds 5,789,806 ordinary shares, representing a 5.94% stake in the company. The disclosure is part of the Irish Takeover Panel regulations under Rule 8.3, which mandates the declaration of positions in relevant securities that represent a 1% or more interest.
Vanguard's report indicates a recent purchase of 1,991 shares at a price of 21.56 USD per unit. However, the filing does not note any engagements in cash-settled or stock-settled derivatives. No indemnity, option arrangements, or agreements related to Avadel's securities were reported either.
No additional agreements or future trading intentions were disclosed, and no Supplemental Form 8 was attached to Vanguard's filing. The details focus strictly on Vanguard's current stake in the pharmaceutical company without revealing strategic intentions.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.